Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biovail has said that Canada's Therapeutic Products Directorate or TPD has approved company's supplemental new drug submission of Wellbutrin XL for the prevention of major depressive illness with an autumn-winter seasonal pattern.
Subscribe to our email newsletter
According to company, this approval of Wellbutrin XL in seasonal major depressive illness represents company’s third notice of compliance in the past six months. Biovail Pharmaceuticals Canada (BPC), the Canadian sales and marketing division of the company will introduce this new indication to Canadian health care professionals in 2008.
Scott Smith, vice-president and general manager of BPC, said: “Seasonal major depressive illness is a serious and often under-diagnosed type of depression. The approval of Wellbutrin XL as a prevention for this type of depression offers new hope to patients who dread the onset of winter, and the episodes of major depression that often come with it.”